《半日速報》恆指半日收報24,250點 升47點; 恆生科技指數半日收報5,305點 升21點 信義光能跌逾4% 中生製藥、京東健康、恆生、偉祿集團、諾誠健華創新高
恆指半日收24,250點,升47點或0.2%。恆生科技指數報5,305點,升21點或0.4%。國指升8點或0.1%,報8,741點。
活躍重磅股表現:
阿里巴巴(09988.HK) 收107.9元,上升1.7%;
美團(03690.HK) 收122.8元,上升1.6%;
平安(02318.HK) 收52.35元,下跌1.3%;
小米集團(01810.HK) 收56.95元,下跌0.6%;
騰訊(00700.HK) 收503元,上升0.6%;
港交所(00388.HK) 收423.6元,無升跌;
異動恆指及國指成份股:
信義光能(00968.HK) 收2.87元,下跌5%;
百濟神州(06160.HK) 收159.3元,上升4.5%;
信義玻璃(00868.HK) 收8.2元,下跌4.4%;
石藥(01093.HK) 收8.3元,上升3.9%;
龍湖(00960.HK) 收10.1元,下跌3.3%;
創科(00669.HK) 收89.65元,上升3%;
中生製藥(01177.HK) 收6.25元,上升3%,創新高;
京東健康(06618.HK) 收44.75元,上升2.3%,創新高;
恆生(00011.HK) 收123.5元,上升2.1%,創新高;
異動綜合中小型股:
健康之路(02587.HK) 收9.69元,上升10.5%;
萬國數據(09698.HK) 收37.95元,上升10.2%;
偉祿集團(01196.HK) 收8.26元,上升6.6%,創新高;
諾誠健華(09969.HK) 收17.28元,上升5.4%,創新高;
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.